APOC4 is currently a under review by the FDA as a biomarker for ovarian cancer (https://edrn.nci.nih.gov/data-and-resources/biomarkers/apoc4/) and demonstrated a high ROC-AUC (0.87) using logistic regression within this study (Figure S7B). This evidence concerns the gene APOC4 and ovarian cancer.